[A22-104] Melphalan flufenamide (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2023
Project no.:
A22-104
Commission:
Commission awarded on 04.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
adults with multiple myeloma who have received at least three prior therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression during or after the last therapy; for patients with prior autologous stem cell transplantation, the time to progression after transplantation should be at least 3 years
added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.